Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects

BACKGROUND AND OBJECTIVES: Edoxaban is an oral, once-daily direct factor Xa inhibitor. To support the possibility that patients may choose to switch treatment from another nonvitamin K antagonist oral anticoagulant to edoxaban, this clinical study was conducted to evaluate the pharmacokinetic and ph...

Descripción completa

Detalles Bibliográficos
Autores principales: Parasrampuria, Dolly A., Weilert, Doris, Maa, Jen-Fue, Dishy, Victor, Kochan, Jarema, Shi, Minggao, Brown, Karen S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4740573/
https://www.ncbi.nlm.nih.gov/pubmed/26597179
http://dx.doi.org/10.1007/s40261-015-0357-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4740573/
https://www.ncbi.nlm.nih.gov/pubmed/26597179
http://dx.doi.org/10.1007/s40261-015-0357-8

Ejemplares similares